Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
Xenon Pharmaceuticals (XENE) Posts Q1 Loss of $0.30/Share
May 12, 2015 4:14 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.30), versus the analyst estimate of $0.14. Revenue for the quarter came in at $4 million versus the consensus estimate of $4.65 million.
Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, "We continue to make good... More
